Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Feb 7;8(6):9005-9006.
doi: 10.18632/oncotarget.14667.

Synthetic microneurotrophins in therapeutics of neurodegeneration

Achille Gravanis  1 , Iosif Pediaditakis  1 , Ioannis Charalampopoulos  1
Affiliations
Editorial

Synthetic microneurotrophins in therapeutics of neurodegeneration

Achille Gravanis et al. Oncotarget. .
No abstract available

Keywords: Neuroscience; agonists; apoptosis; neurodegeneration; neuroinflammation; neurotrophin receptors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Blood-brain-barrier permeable 17-spiro-steroid derivatives bind to and activate neurotrophin receptors, protecting various neurons against apoptosis, in vitro, ex vivo and in vivo in animal models of neurodegenerative diseases. These synthetic microneurotrophins offer a new pharmacological tool to develop non-toxic, blood-brain-barrier permeable neurotrophin receptor agonists and antagonists, potentially effective in the treatment of neurodegenerative diseases, brain trauma and neuropathic pain.
See this image and copyright information in PMC

References

    1. Chao M.V. Nat. Rev. Neurosci. 2003;4:299–309. - PubMed
    1. Charalampopoulos, et al. Proc Natl Acad Sci USA. 2004;101:8209–8214. - PMC - PubMed
    1. Lazaridis, et al. PLoS Biol. 2011;9:e1001051. - PMC - PubMed
    1. Pediaditakis, et al. Endocrinology. 2015;156:16–23. - PubMed
    1. Charalampopoulos, et al. Trends Endocrinol Metab. 2008;19:300–307. - PubMed

Publication types

LinkOut - more resources